Acura Pharmaceuticals : Termination of Material Agreement

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D. C. 20549



FORM 8-K


CURRENT REPORT


Pursuant to...
-Today at 11:24 am- MarketScreener

Related Keywords

Washington ,United States ,New York ,Illinois ,Petera Clemens , ,Commission File Number ,Abuse Deterrent Pharma ,Exchange Commission ,Securities Exchange ,Name Of Each Exchange On Which ,Pfizer Inc ,Zyla Life Sciences ,Development Inc ,Limitx Technology ,Egalet Corporation Zyla ,N North Court ,Growth Company ,Pharmaceuticals Inc ,Acura Pharmaceuticals Inc ,Pfizer ,King Pharmaceuticals Research ,Exact Name ,Each Exchange ,Securities Act ,Exchange Act ,Securities Exchange Act ,Emerging Growth Company ,Material Definitive ,Egalet Corporation ,License Agreement ,Acura Pharmaceuticals ,Effective Date ,Drug Application ,Drug Administration ,Par Pharmaceuticals ,Current Report ,Private Securities Litigation Reform Act ,Markets ,